The Pharmacovigilance Analysis of Adverse Events of Erlotinib Based on the Open Access FAERS Database
February 2026
in “
MedBA Medicine
”
Studysummary This study identified potential new adverse drug reaction signals for erlotinib, used in lung and pancreatic cancer treatment, by analyzing a large dataset of case reports, indicating further clinical studies are necessary to confirm these findings. Our plain-language summary of this paper — not a Tressless recommendation.
This study analyzed adverse events (AEs) associated with erlotinib, a drug used to treat lung and pancreatic cancer, using data from 9,360,316 case reports in the FAERS database. Of these, 2,870 reports identified erlotinib as the primary suspect for AEs, with 177 adverse drug reactions (ADRs) affecting 21 organ systems. While some AEs, like dermatitis acneiform, were consistent with clinical observations, unexpected AEs such as eyelash growth, thoracic metastases, and scarring alopecia were also identified. These findings suggest the need for further clinical studies to confirm these ADRs and improve patient guidance.
